The New Brunswick, N.J., pharmaceutical giant said the FDA accepted the application through its Real-Time Oncology Review program, which allows for an earlier submission of topline efficacy and safety ...

Johnson & Johnson (JNJ) said it has submitted an application to the FDA for its therapy candidate TAR-200 for the treatment of a certain type of bladder cancer. Read more here.

An FDA application for TAR-200 to treat BCG-unresponsive high-risk non-muscle-invasive bladder cancer is under real-time ...

(RTTNews) - Johnson & Johnson (JNJ) Wednesday said it has initiated the submission of new drug application or NDA to Food and Drug Administration (FDA) for TAR-200 to treat patients with Bacillus ...

Johnson & Johnson announced it has initiated the submission of an original New Drug Application with the U.S. FDA for TAR-200 for the ...

The New Drug Application for TAR-200 is supported by results from the Phase IIb SunRISe-1 study, which demonstrated an 83.5% ...

The pharma began submitting its TAR-200 bladder cancer treatment to the FDA. Elsewhere, Sarepta and Madrigal reported strong ...

Promising investigational treatments for NMIBC include TAR-200, apalutamide ... As the year comes to a close, we revisit some of this year’s top content on bladder cancer. There has been a lot of news ...

It's a bright future,” says Siamak Daneshmand, MD. In this video, Siamak Daneshmand, MD, discusses next steps with TAR-200 in patients with non–muscle-invasive bladder cancer (NMIBC). Daneshmand ...

The Food and Drug Administration is banning the use of Red No. 3, an artificial dye linked to cancer in animals, from food and ingested drugs. Johnson & Johnson initiated an application seeking Food ...

Joshua Meeks, MD, Ph.D. Joshua Meeks addresses the BCG shortage in bladder cancer treatment, presenting alternative options including gemcitabine + docetaxel and novel therapies like TAR-200 and ...

Gemcitabine (TAR-200) is under development for the treatment of upper tract urothelial carcinomas including non-muscle invasive bladder cancer (NMIBC), muscle-invasive transitional cell carcinoma of ...